Bayer will present new data on its entire prostate cancer portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU), to be held in San Francisco, USA, January 25-27, 2024.

Data on darolutamide will include post-hoc sensitivity analyses of the phase III ARASENS trial, evaluating overall survival with darolutamide and androgen deprivation therapy (ADT) plus docetaxel in patients with hormone-sensitive metastatic prostate cancer (mHSPC).

A separate analysis of the same trial comparing hospitalization rates and length of hospital stay during and after docetaxel will also be presented.

An overview will be provided for the ongoing Phase III ARASTEP trial investigating whether darolutamide plus ADT improves radiological progression-free survival.

The group will also present the Phase II ARAMON trial comparing the effect of darolutamide to enzalutamide monotherapy on serum testosterone levels in patients with castration-sensitive prostate cancer after biochemical recurrence.

Darolutamide is approved under the brand name Nubeqa TM in over 85 countries worldwide for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). It is also approved for the treatment of patients with mHSPC in over 75 markets, including the USA, Japan, the EU and China.

Copyright (c) 2024 CercleFinance.com. All rights reserved.